Wednesday, July 8, 2026

Patent intelligence · US

US 11725005

Compositions and methods for inhibiting kinases

granted A61KA61K2300/00A61K31/506A61K45/06
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 9
Patent details — US 11725005
Jurisdiction
US
Status
granted
Grant date
Aug 15, 2023
Expiration
Aug 10, 2043
Claims
1
CPC classes
A61K, A61K2300/00, A61K31/506, A61K45/06
View on Google Patents ↗

Quick answer

US 11725005 (Compositions and methods for inhibiting kinases) is held by Inhibikase Therapeutics, Inc.. Status: granted. Granted Aug 15, 2023. Expires Aug 10, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
1
CPC classes
A61K, A61K2300/00, A61K31/506, A61K45/06, A61P, A61P31/04

More from Inhibikase Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 11407747

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Expires Aug 4, 2042

    granted
  2. US 10906896

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Expires Jan 28, 2041

    granted
  3. US 10344027

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Expires Jul 4, 2039

    granted
  4. US 10316031

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Expires Jun 6, 2039

    granted
  5. US 10118923

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Expires Nov 1, 2038

    granted
  6. US 9907796

    Methods of treating tumoral diseases, or bacterial or viral infections

    Inhibikase Therapeutics, Inc. · Expires Mar 1, 2038

    granted
  7. US 9828370

    Compositions and methods for inhibiting kinases

    Inhibikase Therapeutics, Inc. · Expires Nov 23, 2037

    granted

Frequently asked questions

What is US patent 11725005?

US 11725005 (Compositions and methods for inhibiting kinases) is held by Inhibikase Therapeutics, Inc.. Status: granted. Granted Aug 15, 2023. Expires Aug 10, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11725005?

Inhibikase Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.

When does US 11725005 expire?

Our index shows an expiration date of Aug 10, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.